JENNIFER LAZZARA: Open Payments
NPI 1720503881 · MURRAY, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,572 in 63 payments from 27 companies in 2025. Trend: 2023 $4,042 · 2024 $3,299 · 2025 $1,572
Food & beverage: $1,572
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $191 |
| Novartis Pharmaceuticals Corporation | 8 | $156 |
| PFIZER INC. | 9 | $151 |
| GENZYME CORPORATION | 1 | $150 |
| Koya Medical, Inc. | 1 | $108 |
| Myriad Genetic Laboratories, Inc. | 3 | $76 |
| Merck Sharp & Dohme LLC | 3 | $71 |
| Astellas Pharma US Inc | 3 | $69 |
| Genentech USA, Inc. | 3 | $61 |
| ARRAY BIOPHARMA INC | 2 | $47 |
Products named: SARCLISA, KOYA MEDICAL, KISQALI, KEYTRUDA, ENHERTU, IMFINZI, Vyloy, XALKORI.
Industry payments across UT — which companies pay providers there.
